05/02/2026 - Press release
Infections caused by Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii are identified as priorities for clinical research. The study, published in the Journal of Infection and Public Health, involved 60 experts who reached consensus on the main priorities for the development of new clinical trials. The work carried out within the MePRAM project of CIBER has resulted in several priority lists-microorganisms, clinical syndromes, patient populations and anti-infective treatments-aimed at guiding future research from a personalised medicine approach.
Més informació "The roadmap for clinical research against antibiotic resistance established"
11/12/2025 - Press release
The research team led by the Institut de Recerca Joan de Déu (IRSJD) and the Hospital del Mar Research Institute has, for the first time, demonstrated the efficacy of a drug in animal models developed from samples of patients from the Sant Joan de Déu Hospital. The study identifies the PRKG1 gene as a key element in the biology of rhabdomyosarcoma and as a potential biomarker to predict treatment response. The determination of Cristina's parents-a girl who passed away from rhabdomyosarcoma in 2015-has been crucial in making this study possible. Their commitment enabled the raising of more than €600,000 to promote research into new treatments for this type of pediatric tumor.
25/11/2025 - Institutional news
Dr. César Jessé Enríquez has received the award for the best oral presentation in the area of the CIBER of Respiratory Diseases (CIBERES) during the Joint Training Days between the CIBER area of Respiratory Diseases (CIBERES) and the CIBER area of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), focused on early-career researchers. The event took place at Euroforum El Escorial on November 6 and 7.
Més informació "Award for César Jessé Enríquez at the joint training days of CIBER-BBN and CIBERES"
04/11/2025 - General information
The Pharmacokinetics and Pharmacodynamics (PK/PD) Research Team at Hospital del Mar has received a competitive international grant awarded by the pharmaceutical company Pfizer, as part of the "Independent Research Grant Program - Pharmacokinetics-pharmacodynamics (PK/PD) of Aztreonam-Avibactam (ATM-AVI) in Special Populations." The selected project, chosen among proposals from several European centers, aims to optimize the use of the new antibiotic aztreonam-avibactam in patients with renal impairment - a population particularly vulnerable to severe infections caused by multidrug-resistant bacteria. The project is led by Dr. Mila Montero and Dr. Sònia Luque.
Més informació "Pfizer International Grant for a Project at Hospital del Mar on Antibiotic Therapy"
22/10/2025 - General information
The Hemodynamics Unit of the Cardiology Department at Hospital del Mar took part in a study published in the New England Journal of Medicine. The study demonstrates that one month after undergoing treatment for a myocardial infarction, patients can safely continue therapy with a single antiplatelet drug without added risk.
05/08/2025 - Press release
70% of Chronic Obstructive Pulmonary Disease (COPD) cases go undiagnosed. Now, a study led by Hospital del Mar and the Hospital del Mar Research Institute has validated ten metabolites that are altered in patients with this disease. These metabolites can be identified through a simple blood test, which opens the door to their use in future population-based screening for suspected COPD. The study used artificial intelligence tools to determine which of these molecules yielded the most accurate results.
Més informació "Progress Toward a Population Screening Test for COPD"
29/07/2025 - Institutional news
One of the symptoms associated with long COVID is chronic fatigue. Until now, its origin was unclear. A study conducted by the Pneumology, Pathology, and Intensive Care Services at Hospital del Mar, along with researchers from the Hospital del Mar Research Institute, points to a potential cause: fibrosis in the walls of blood vessels triggered by the infection. The study has been published in the journal Ultrastructural Pathology. The research is based on muscle biopsies taken from the quadriceps of 35 patients admitted to Hospital del Mar during the pandemic. Eight of these samples were analyzed using electron microscopy to assess the state of the tissue. Significant fibrosis was found in the walls of the capillaries supplying blood to the muscle fibers, a finding consistent with observations in other organs from patients who died from COVID-19.
Més informació "One of the Possible Causes of Chronic Fatigue in People with Long COVID Identified"
27/06/2025 - General information
Dr. Alicia Prieto, researcher at the Heart Disease Research Group of the Hospital del Mar Research Institute of Barcelona (HMRIB) and cardiologist at Hospital del Mar, has been awarded one of the three Daniel Bravo Foundation Fellowships to carry out advanced research in cardiology at leading international centers, including the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ).
20/06/2025 - Press release
People with Chronic Obstructive Pulmonary Disease (COPD) who suffer from sarcopenia, or loss of muscle capacity, have higher levels of a protein called myostatin, which, under normal conditions, helps regulate muscle growth. Elevated levels of this protein trigger a series of reactions in the muscle cells, preventing regeneration and growth after damage, leading to muscle mass loss in these patients. This was revealed by a study from the Hospital del Mar and the Hospital del Mar Research Institute, which opens the door to developing treatments targeted at this protein to reverse this situation.
Més informació "Researchers Discover the Cause of Muscle Loss in Some COPD Patients"
20/05/2025 - Press release
A study from the Hospital del Mar, the Hospital del Mar Research Institute, and the Reference Laboratory of Catalonia validates the effectiveness of combining a molecule, apotransferrin, with existing antibiotics to treat the antibiotic-resistant bacteria Pseudomonas aeruginosa. The research, published in the International Journal of Antimicrobial Agents, opens the door to a new strategy for tackling the problem of antibiotic-resistant bacteria by preventing them from accessing the iron they need to complete their life cycle. The new drug combination enhances the ability of antibiotics. Additionally, apotransferrin is a drug already used in other diseases, which could facilitate its use in bacterial infections.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
